Response to the letter to the editor on "an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy"

Expert Opin Pharmacother. 2019 Aug;20(12):1529-1530. doi: 10.1080/14656566.2019.1620987. Epub 2019 May 24.

Authors

Hollis Lin¹, Sonalee Agarwal¹, Marissa Betts², Kyle Fahrbach², Madhura Chitnis², Michael Polydefkis³

Affiliations

¹ Alnylam Pharmaceuticals , Cambridge , MA , USA.
² Evidera , Waltham , MA , USA.
³ Department of Neurology, Johns Hopkins University , Baltimore , MD , USA.

PMID: 31124741
DOI: 10.1080/14656566.2019.1620987

No abstract available

Keywords: Transthyretin amyloid polyneuropathy; indirect treatment comparison.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Amyloid Neuropathies, Familial*
Benzoxazoles
Humans
Polyneuropathies*
Prealbumin
RNA, Small Interfering

Substances

Benzoxazoles
Prealbumin
RNA, Small Interfering
patisiran
tafamidis